Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Continuing Operations (2016 - 2025)

Coherus Oncology's Income from Continuing Operations history spans 13 years, with the latest figure at 46347000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 0.55% year-over-year to 46347000.0; the TTM value through Dec 2025 reached 183124000.0, down 1.89%, while the annual FY2025 figure was 183124000.0, 14.98% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 46347000.0 at Coherus Oncology, down from 44517000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 10751000.0 in Q3 2024 and bottomed at 172947000.0 in Q1 2021.
  • The 5-year median for Income from Continuing Operations is 46872500.0 (2025), against an average of 58977950.0.
  • The largest annual shift saw Income from Continuing Operations tumbled 586.19% in 2021 before it surged 72.88% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 45683000.0 in 2021, then dropped by 28.87% to 58870000.0 in 2022, then tumbled by 35.3% to 79653000.0 in 2023, then skyrocketed by 42.13% to 46093000.0 in 2024, then decreased by 0.55% to 46347000.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Income from Continuing Operations are 46347000.0 (Q4 2025), 44517000.0 (Q3 2025), and 44862000.0 (Q2 2025).